X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.fiercepharma.com/pharma/jjs-balversa-gets-mixed-approval-bladder-cancer-amid-fda-scrutiny-patient-survival-subgroup
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-erdafitinib-locally-advanced-or-metastatic-urothelial-carcinoma
https://www.globenewswire.com//news-release/2023/10/22/2764324/0/en/First-Results-with-Erdafitinib-Releasing-Intravesical-Delivery-System-TAR-210-Show-Early-Evidence-of-Positive-Clinical-Activity-in-Patients-with-Non-Muscle-Invasive-Bladder-Cancer-.html
https://www.globenewswire.com//news-release/2023/10/21/2764287/0/en/Results-from-Phase-2-THOR-2-Study-Showed-Improved-Rates-of-Recurrence-Free-Survival-in-Patients-with-High-Risk-Non-Muscle-Invasive-Bladder-Cancer-with-Select-Fibroblast-Growth-Fact.html
https://www.globenewswire.com//news-release/2023/09/08/2739919/0/en/Janssen-Submits-Marketing-Authorisation-Application-to-the-European-Medicines-Agency-Seeking-Approval-of-Erdafitinib-for-the-Treatment-of-Patients-with-Locally-Advanced-or-Metastat.html
https://www.prnewswire.com/news-releases/janssen-submits-supplemental-new-drug-application-to-the-us-food-and-drug-administration-seeking-full-approval-of-balversa-erdafitinib-for-the-treatment-of-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma-and-301911509.html
https://www.onclive.com/view/erdafitinib-elicits-responses-in-fgfr-altered-solid-tumors
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-erdafitinib-tablets-41169.pdf
https://www.fiercepharma.com/pharma/asco-jjs-balversa-tops-chemotherapy-bladder-cancer-trial
https://www.globenewswire.com/news-release/2023/06/05/2682059/0/en/Janssen-Announces-Erdafitinib-Improved-Overall-Survival-Versus-Chemotherapy-in-Patients-with-Metastatic-or-Unresectable-Urothelial-Carcinoma-and-Selected-Fibroblast-Growth-Factor-R.html
https://www.prnewswire.com/news-releases/janssen-presents-initial-results-from-the-phase-2-ragnar-study-of-balversa-erdafitinib-in-patients-with-advanced-solid-tumors-with-fgfr-alterations-301562217.html
https://www.globenewswire.com/news-release/2022/01/31/2376027/0/en/Non-Muscle-Invasive-Bladder-Cancer-Pipeline-Insights-Clinical-Trials-Report-2022-by-DelveInsight.html
https://www.biospace.com/article/releases/janssen-presents-results-from-phase-1b-2-norse-study-in-patients-with-metastatic-or-locally-advanced-urothelial-carcinoma-treated-with-balversa-erdafitinib-in-combination-with-cetrelimab-a-pd-1-inhibitor/?s=71
https://www.biopharmadive.com/news/immunomedics-resubmits-fda-breast-cancer-drug-sacituzumab/568350/
https://www.fiercebiotech.com/biotech/u-k-drug-discovery-startup-healx-taps-gsk-astex-alum-as-cso
http://www.pmlive.com/pharma_news/j_and_js_targeted_bladder_cancer_treatment_gets_us_approval_1284473
https://www.prnewswire.com/news-releases/balversa-erdafitinib-receives-us-fda-approval-for-the-treatment-of-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma-with-certain-fgfr-genetic-alterations-300831503.html
Market Place
Share 
